Media coverage about ViewRay (NASDAQ:VRAY) has been trending somewhat positive this week, according to Accern. Accern rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. ViewRay earned a coverage optimism score of 0.14 on Accern’s scale. Accern also gave news headlines about the company an impact score of 45.4043054563963 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Here are some of the news headlines that may have impacted Accern’s analysis:

Several analysts recently commented on the stock. ValuEngine lowered shares of ViewRay from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Northland Securities reissued a “buy” rating and set a $10.00 target price on shares of ViewRay in a research note on Friday, November 17th. Finally, Mizuho reissued a “buy” rating and set a $12.00 target price on shares of ViewRay in a research note on Monday, November 13th. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. ViewRay has a consensus rating of “Buy” and an average price target of $10.60.

ViewRay (NASDAQ VRAY) traded up $0.05 during mid-day trading on Friday, hitting $8.82. 441,100 shares of the stock were exchanged, compared to its average volume of 730,797. ViewRay has a twelve month low of $3.01 and a twelve month high of $10.39. The company has a current ratio of 1.59, a quick ratio of 1.20 and a debt-to-equity ratio of -1.67.

ViewRay (NASDAQ:VRAY) last released its quarterly earnings results on Monday, November 13th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.07). The firm had revenue of $12.20 million for the quarter, compared to analyst estimates of $18.63 million. The company’s revenue for the quarter was up 2950.0% on a year-over-year basis. equities research analysts anticipate that ViewRay will post -0.93 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Impact ViewRay (VRAY) Stock Price” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at

ViewRay Company Profile

ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.

Insider Buying and Selling by Quarter for ViewRay (NASDAQ:VRAY)

Receive News & Stock Ratings for ViewRay Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ViewRay Inc. and related stocks with our FREE daily email newsletter.